Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $472000.0.

  • Autolus Therapeutics' Other Non-Current Liabilities rose 559.28% to $472000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $472000.0, marking a year-over-year increase of 559.28%. This contributed to the annual value of $426000.0 for FY2024, which is 1932.77% up from last year.
  • Autolus Therapeutics' Other Non-Current Liabilities amounted to $472000.0 in Q3 2025, which was up 559.28% from $477000.0 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Other Non-Current Liabilities high stood at $477000.0 for Q2 2025, and its period low was $105000.0 during Q3 2022.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $326000.0 (2023), whereas its average is $285375.0.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first crashed by 937.5% in 2022, then surged by 25877.19% in 2024.
  • Autolus Therapeutics' Other Non-Current Liabilities (Quarter) stood at $128000.0 in 2021, then decreased by 9.38% to $116000.0 in 2022, then soared by 207.76% to $357000.0 in 2023, then rose by 19.33% to $426000.0 in 2024, then rose by 10.8% to $472000.0 in 2025.
  • Its Other Non-Current Liabilities was $472000.0 in Q3 2025, compared to $477000.0 in Q2 2025 and $444000.0 in Q1 2025.